Open AccessImmunohistochemical and Molecular Studies of p53 and KRAS Protein and Their Relations to Colorectal Carcinoma
Author(s) -
Merza H. Homady,
Tanya S. Salih,
Mariamm M. Al-Jubori,
Mustafa D. Younus
Publication year - 2021
Publication title -
cihan university-erbil scientific journal
Language(s) - English
Resource type - Journals
eISSN - 2707-6377
pISSN - 2519-6979
DOI - 10.24086/cuesj.v5n1y2021.pp28-33
Subject(s) - kras , colorectal cancer , genotype , immunohistochemistry , gene , medicine , cancer research , biology , oncology , cancer , genetics
The study inc1uded 50 tissue blocks embedded in paraffin wax (16 females and 34 males), obtained from a patients group with (CRC) colorectal cancer , as well as 35 Tissue blocks that were embedded in paraffin wax from norma1 co1on (ulcerative co1itis) as controls. A relatively few oncogenes and most prominently tumor-suppressing genes, Kirastien rat sarcoma virus (KRAS), and P53 genes have been mutated into a significant part of CRCs, and a broad collection of mutated genes has been defined in CRC subsets. Current findings showed very significant differences between patients and control subjects in the p53 positive rate (P<0.001). TP53 Pro/Pro genotype positivity was higher in the contro1 group I than in the patient group I and this was a significant difference (Pi<0.001) with an odd ratio of less than one. The genotype Pro/Pro was considered to be protective against colorectal carcinoma preventively fractured 0.767. The positive rate of p53 Arg/Arg genotype in patients was more frequent and statistically significant (P <0.01), because the odd ratio was more than one. The genotype Arg/Arg would be considered a colorectal carcinoma risk factor. We conclude that p53 over expression is used as an indicator of p53 mutation (as identified by immuno-historic chemistry) and KRAS protein expression was negatively impaired for all the patients in the current study.